文献速递临床试验与 GCP

ALBINO试验详细统计分析计划:别嘌醇联合低温治疗对缺氧缺血性脑损伤神经认知结局的影响——一项盲法随机安慰剂对照平行组多中心优效性III期试验

Detailed statistical analysis plan for ALBINO: effect of Allopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome - a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III).
PubMed 文献 · Trials · 2024-01-24

ALBINO试验是一项研究者发起的随机、安慰剂对照、双盲、多国平行组优效性III期试验,评估出生后立即给予别嘌醇对(近)足月新生儿缺氧缺血性脑病(HIE)的疗效与安全性。主要终点为2岁时存活伴神经发育损害、死亡或无损害存活的三分类结局,主要分析采用广义logit模型在意向性治疗(ITT)人群中进行,并按两个治疗组分层。本统计分析计划在数据分析前发布,符合赫尔辛基宣言和国际协调会良好临床实践指南。

要点

  • 主要终点为2岁时存活伴神经发育损害、死亡或无损害存活的三分类结局。
  • 主要分析采用广义logit模型,在意向性治疗(ITT)人群中进行,并按两个治疗组分层。
  • 统计分析计划在数据分析前制定并发布,符合赫尔辛基宣言和ICH GCP指南。

核心结论

  • ALBINO试验旨在评估出生后立即给予别嘌醇对(近)足月新生儿HIE的疗效与安全性,主要终点为2岁时神经发育结局。
  • 本统计分析计划在数据分析前发布,符合赫尔辛基宣言和国际协调会良好临床实践指南。

研究设计与样本

  • ALBINO试验为研究者发起的随机、安慰剂对照、双盲、多国平行组优效性III期试验,研究对象为有HIE早期体征的(近)足月新生儿。
  • 主要分析采用广义logit模型(依据Bishop、Fienberg、Holland方法)在意向性治疗(ITT)人群中进行,并按两个治疗组分层。

关键数值与推荐

  • 主要终点为2岁时存活伴神经发育损害、死亡或无损害存活的三分类结局。
  • 主要分析采用广义logit模型在意向性治疗(ITT)人群中进行,并按两个治疗组分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite therapeutic hypothermia (TH) and neonatal intensive care, 45-50% of children affected by moderate-to-severe neonatal hypoxic-ischemic encephalopathy (HIE) die or suffer from long-term neurodevelopmental impairment. Additional neuroprotective therapies are sought, besides TH, to further improve the outcome of affected infants. Allopurinol - a xanthine oxidase inhibitor - reduced the production of oxygen radicals and subsequent brain damage in pre-clinical and preliminary human studies of cerebral ischemia and reperfusion, if administered before or early after the insult. This ALBINO trial aims to evaluate the efficacy and safety of allopurinol administered immediately after birth to (near-)term infants with early signs of HIE. METHODS/DESIGN: The ALBINO trial is an investigator-initiated, randomized, placebo-controlled, double-blinded, multi-national parallel group comparison for superiority investigating the effect of allopurinol in (near-)term infants with neonatal HIE. Primary endpoint is long-term outcome determined as survival with neurodevelopmental impairment versus death versus non-impaired survival at 2 years. RESULTS: The primary analysis with three mutually exclusive responses (healthy, death, composite outcome for impairment) will be on the intention-to-treat (ITT) population by a generalized logits model according to Bishop, Fienberg, Holland (Bishop YF, Discrete Multivariate Analysis: Therory and Practice, 1975) and ."will be stratified for the two treatment groups. DISCUSSION: The statistical analysis for the ALBINO study was defined in detail in the study protocol and implemented in this statistical analysis plan published prior to any data analysis. This is in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. TRIAL REGISTRATION: ClinicalTrials.gov NCT03162653. Registered on 22 May 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Engel C, Rüdiger M, Benders MJNL, et al. Detailed statistical analysis plan for ALBINO: effect of Allopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome - a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III). Trials. 2024. PMID: 38267942. doi:10.1186/s13063-023-07828-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。